IGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
The following is a brief description of each matter voted upon at
Ignyta, Inc.s (the Registrant) annual meeting of stockholders on
June13, 2017, and the number of votes cast for, withheld or
against, the number of abstentions and the number of broker
non-votes with respect to each matter, as applicable.
1. To reelect the following two directors for a three-year term
to expire at the 2020 annual meeting of stockholders:
|
Director Name |
For | Withheld | ||||||
|
Jonathan E. Lim, M.D. |
29,598,356 | 49,574 | ||||||
|
James Bristol, Ph.D. |
29,264,687 | 383,243 |
In accordance with the above results, each nominee was reelected
to serve as a director.
2. To ratify the selection of KPMG LLP as the Registrants
independent registered public accounting firm for the fiscal year
ending December31, 2017:
| For | Against | Abstain | Broker Non-Votes | |||
| 35,525,453 | 5,732 | 1,675 |
In accordance with the above results, the selection of KPMG LLP
was ratified.
About IGNYTA, INC. (NASDAQ:RXDX)
Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.
